Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIO-902 in Type 2 Diabetes Mellitus
NCT00622089Phase 3Terminated
- Sponsor
- DiObex, Inc.
- Start
- Jan 2008
- Primary completion
- Dec 2008
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of levoketoconazole in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by DiObex, Inc. Primary endpoints: Proportion of subjects who reach the lipid goal at 24 weeks and Proportion of subjects who meet the HbA1c goal at 24 weeks. Started Jan 2008; status: terminated.
02
Drugs
levoketoconazole
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00622089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00622089.